Comparative Pharmacology
Head-to-head clinical analysis: CHOLETEC versus OMNIPAQUE 9.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLETEC versus OMNIPAQUE 9.
CHOLETEC vs OMNIPAQUE 9
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Choletec is a technetium-99m labeled iminodiacetic acid derivative used for hepatobiliary scintigraphy. It is taken up by hepatocytes via organic anion transporting polypeptides and excreted into bile canaliculi via multidrug resistance-associated protein 2, allowing visualization of the biliary system.
Iodinated nonionic contrast agent that attenuates X-rays, enhancing vascular and tissue contrast. Its iodine content (350 mg/mL) provides radiopacity, while low osmolality reduces adverse hemodynamic effects.
1 gram intravenously every 8 hours; maximum 3 g/day.
Omnipaque 9 (iohexol 9 mg I/mL) is administered intravenously. For CT enhancement, typical adult dose is 50-100 mL (450-900 mg I) by slow IV injection.
None Documented
None Documented
Terminal elimination half-life is approximately 16–24 hours; clinically, once-daily dosing achieves steady-state after 5–7 days, allowing for pharmacological effects on bile acid composition.
Terminal elimination half-life: 1–2 hours in patients with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Primarily biliary (approx. 50–70% as unchanged drug and metabolites) with fecal elimination; renal excretion is minimal (<5% unchanged).
Renal: >95% unchanged via glomerular filtration; fecal: <1%.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent